| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | 52.99 |
| 2 | Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. | J Clin Oncol | 2014 | 9.86 |
| 3 | A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). | Clin Cancer Res | 2013 | 1.08 |